Last reviewed · How we verify
Alemtuzumab immunotherapy
At a glance
| Generic name | Alemtuzumab immunotherapy |
|---|---|
| Sponsor | Samuel Forrester Hunter, MD, PhD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Autologous Stem Cell Transplantation for Crohn's Disease (PHASE1, PHASE2)
- COMparison Between All immunoTherapies for Multiple Sclerosis.
- CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia (PHASE1)
- Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim (PHASE2)
- Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia
- Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects (PHASE1)
- T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant (PHASE2)
- Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alemtuzumab immunotherapy CI brief — competitive landscape report
- Alemtuzumab immunotherapy updates RSS · CI watch RSS
- Samuel Forrester Hunter, MD, PhD portfolio CI